Is this posted somewhere already?
https://twitter.com/user/status/1918337911264825734
Update on Patient #1 in Our Pemgarda + Paxlovid Case Study
Six days ago, the first patient in our case series received a combination treatment of Pemgarda monoclonal antibodies and Paxlovid, under the care of his physician.
We know so many of you are curious as to how he’s doing - here’s his symptom update:
*****
“Since the first Pemgarda infusion, I've observed an 80% reduction in brain fog, a 50–70% improvement in sleep quality, and a similar reduction in chronic inflammation-related symptoms.
However, post-exertional malaise has significantly worsened in the week following treatment. Light activities that were previously tolerable now trigger a PEM crash.
Not clear if this represents a temporary response related to immune system activity following antibody infusion, will continue to monitor and share updates.”
*****
Our team is cautiously optimistic about the possible results of this treatment - although it’s still too early to gauge the long-term outcome.
We’re very glad to hear about the patient's 80% reduction in Long COVID brain fog, which seems quite significant.
As for his post-exertional malaise (or PEM for short), the patient will continue to monitor this closely. While the causes of PEM are not yet well understood, research gets closer every day to uncovering the cause- and we hope our work will add to that. Although we can’t yet say for sure, it’s indeed possible that this symptom marks changes associated with the therapeutic mechanism of action of the drug.
https://twitter.com/user/status/1918337911264825734
Update on Patient #1 in Our Pemgarda + Paxlovid Case Study
Six days ago, the first patient in our case series received a combination treatment of Pemgarda monoclonal antibodies and Paxlovid, under the care of his physician.
We know so many of you are curious as to how he’s doing - here’s his symptom update:
*****
“Since the first Pemgarda infusion, I've observed an 80% reduction in brain fog, a 50–70% improvement in sleep quality, and a similar reduction in chronic inflammation-related symptoms.
However, post-exertional malaise has significantly worsened in the week following treatment. Light activities that were previously tolerable now trigger a PEM crash.
Not clear if this represents a temporary response related to immune system activity following antibody infusion, will continue to monitor and share updates.”
*****
Our team is cautiously optimistic about the possible results of this treatment - although it’s still too early to gauge the long-term outcome.
We’re very glad to hear about the patient's 80% reduction in Long COVID brain fog, which seems quite significant.
As for his post-exertional malaise (or PEM for short), the patient will continue to monitor this closely. While the causes of PEM are not yet well understood, research gets closer every day to uncovering the cause- and we hope our work will add to that. Although we can’t yet say for sure, it’s indeed possible that this symptom marks changes associated with the therapeutic mechanism of action of the drug.
